TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trinity Biotech PLC (TRIB) is not a strong buy for a beginner investor with a long-term focus at this time. The stock shows weak financial performance, no significant positive catalysts, and lacks strong technical or trading signals to justify immediate investment. It is better to hold off on investing in this stock until there are clearer signs of improvement in financials or market sentiment.
The MACD is slightly positive and expanding, indicating minor bullish momentum. However, the RSI is neutral at 55.52, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 0.639, and resistance levels are at 0.761 and 0.799. Overall, the technical indicators do not strongly support a buy decision.
The gross margin increased by 21.54% YoY in Q3 2024, which is a positive sign for operational efficiency.
Revenue growth is minimal at 3.24% YoY, while net income dropped significantly by -29.19% YoY, and EPS declined by -81.82% YoY. There is no recent news or significant insider or hedge fund activity, and the stock's trend suggests a likelihood of short-term declines.
In Q3 2024, revenue increased slightly to $15.15M (+3.24% YoY), but net income dropped to -$4.76M (-29.19% YoY), and EPS fell to -0.04 (-81.82% YoY). Gross margin improved to 35.44% (+21.54% YoY), indicating better cost management but insufficient to offset declining profitability.
No recent analyst ratings or price target changes are available for TRIB, leaving no clear guidance from Wall Street on the stock's potential.
